VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Cancer Her-2/neu Protein Subunit Vaccine
Vaccine Information
  • Vaccine Name: Cancer Her-2/neu Protein Subunit Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0011363
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: ERBB2
  • ERBB2 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0001147
    • Description: Gerbu Adjuvant and recombinant IL-2 (Wagner et al., 2007).
  • Adjuvant:
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: FVB/N, BALB/c
  • Vaccination Protocol: FVB/N transgenic mice spontaneously developing c-neu overexpressing breast cancers were used. Mice were immunized with the combination of the three peptides P4, P6, and P7 coupled to tetanus toxoid (TT-conjugates; BALB/c and FVB/N n = 5/group, MMTV-c-neu trangenic mice n = 8/group) using 15 μg of each peptide conjugate or with co-applicated IL-12 (BALB/c and FVB/N n = 5/group, MMTV-c-neu trangenic mice n = 7/group). Control BALB/c and FVB/N mice (n = 5/group) received TT and control MMTV-c-neu transgenic mice received TT (n = 8) or IL-12 (n = 5) alone or remained unimmunized (n = 8) (Wagner et al., 2007).
  • Efficacy: At the time all untreated mice had developed tumors about 40% of peptide-immunized mice and nearly 60% of mice immunized with the peptide vaccine co-applied with IL-12 remained tumor free (Wagner et al., 2007).
References
Wagner et al., 2007: Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast cancer research and treatment. 2007; 106(1); 29-38. [PubMed: 17203384].